{
    "organizations": [],
    "uuid": "f40f550027e2c566a8ee5dfee32c118b33c87a12",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-regenxbio-and-avexis-announce-expa/brief-regenxbio-and-avexis-announce-expansion-of-relationship-for-spinal-muscular-atrophy-treatments-idUSFWN1P30PJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Avexis Inc:\n* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY\n* REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS\n* REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIOâ€˜S CONSENT\n* REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA\n* REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:08:00.000+02:00",
    "crawled": "2018-01-09T16:57:49.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "avexis",
        "inc",
        "regenxbio",
        "avexis",
        "announce",
        "expansion",
        "relationship",
        "amended",
        "license",
        "agreement",
        "development",
        "commercialization",
        "treatment",
        "spinal",
        "muscular",
        "atrophy",
        "regenxbio",
        "inc",
        "could",
        "receive",
        "million",
        "including",
        "million",
        "guaranteed",
        "upfront",
        "annual",
        "payment",
        "regenxbio",
        "inc",
        "amended",
        "agreement",
        "permit",
        "assignment",
        "avexis",
        "upon",
        "change",
        "control",
        "without",
        "regenxbio",
        "consent",
        "regenxbio",
        "inc",
        "avexis",
        "acquires",
        "exclusive",
        "right",
        "entire",
        "nav",
        "technology",
        "platform",
        "development",
        "treatment",
        "sma",
        "regenxbio",
        "product",
        "developed",
        "treatment",
        "sma",
        "using",
        "nav",
        "aav9",
        "vector",
        "co",
        "receive",
        "low",
        "royalty",
        "net",
        "sale",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}